NASDAQ:AIMT - Aimmune Therapeutics Stock Price, News, Headlines & Rumors Sign in or create an account to add this stock to your watchlist. Get Started $27.90 -0.11 (-0.39 %) (As of 08/17/2018 03:01 AM ET)Previous Close$28.01Today's Range$27.61 - $28.5052-Week Range$18.74 - $42.00Volume321,400 shsAverage Volume686,971 shsMarket Capitalization$1.66 billionP/E Ratio-10.69Dividend YieldN/ABeta-0.24 Company ProfileAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy. The company has strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California. Receive AIMT News and Ratings via Email Sign-up to receive the latest news and ratings for AIMT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:AIMT CUSIPN/A Webwww.aimmune.com Phone650-614-5220 Debt Debt-to-Equity RatioN/A Current Ratio8.22 Quick Ratio8.22 Price-To-Earnings Trailing P/E Ratio-10.69 Forward P/E Ratio-7.90 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book Value$3.50 per share Price / Book7.97 Profitability EPS (Most Recent Fiscal Year)($2.61) Net Income$-131,320,000.00 Net MarginsN/A Return on Equity-69.64% Return on Assets-62.00% Miscellaneous Employees131 Outstanding Shares58,480,000Market Cap$1.66 billion Aimmune Therapeutics (NASDAQ:AIMT) Frequently Asked Questions What is Aimmune Therapeutics' stock symbol? Aimmune Therapeutics trades on the NASDAQ under the ticker symbol "AIMT." How were Aimmune Therapeutics' earnings last quarter? Aimmune Therapeutics Inc (NASDAQ:AIMT) issued its earnings results on Wednesday, August, 8th. The biotechnology company reported ($0.91) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.86) by $0.05. View Aimmune Therapeutics' Earnings History. When is Aimmune Therapeutics' next earnings date? Aimmune Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, November, 5th 2018. View Earnings Estimates for Aimmune Therapeutics. What price target have analysts set for AIMT? 8 Wall Street analysts have issued 1-year price targets for Aimmune Therapeutics' shares. Their forecasts range from $30.00 to $80.00. On average, they anticipate Aimmune Therapeutics' stock price to reach $55.2513 in the next twelve months. This suggests a possible upside of 98.0% from the stock's current price. View Analyst Price Targets for Aimmune Therapeutics. What is the consensus analysts' recommendation for Aimmune Therapeutics? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aimmune Therapeutics in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aimmune Therapeutics. What are Wall Street analysts saying about Aimmune Therapeutics stock? Here are some recent quotes from research analysts about Aimmune Therapeutics stock: 1. According to Zacks Investment Research, "Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company's characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. " (7/24/2018) 2. Cantor Fitzgerald analysts commented, "A stock now perhaps better suited for investors than traders. In our view, the investment profile for AIMT stock changed significantly once top-line data from the Phase 3 PALISADE trial were released. Aside from the company’s IPO, maybe, the data release constitutes the most important event in the company’s history, we believe. Although AIMT plans to develop other treatments, because peanut allergy is the most prevalent food allergy, the NPV of additional therapies is probably lower than that of AR101. We suspect, too, that the market may discount a higher pTS for other programs now that POC has been established." (5/9/2018) Who are some of Aimmune Therapeutics' key competitors? Some companies that are related to Aimmune Therapeutics include GALAPAGOS NV/S (GLPG), United Therapeutics (UTHR), Catalent (CTLT), Dr.Reddy's Laboratories (RDY), Ligand Pharmaceuticals (LGND), FibroGen (FGEN), Loxo Oncology (LOXO), Agios Pharmaceuticals (AGIO), HUTCHISON CHINA/S (HCM), Taro Pharmaceutical Industries (TARO), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals PLC- (GWPH), Madrigal Pharmaceuticals (MDGL), Endo International (ENDP) and Horizon Pharma (HZNP). Who are Aimmune Therapeutics' key executives? Aimmune Therapeutics' management team includes the folowing people: Mr. Eric H. Bjerkholt, Chief Financial Officer (Age 58)Mr. Jeffrey H. Knapp, Chief Operating Officer (Age 52)Mr. Douglas T. Sheehy, Gen. Counsel & Sec. (Age 51)Dr. Daniel C. Adelman, Chief Medical Officer (Age 61)Dr. Stephen George Dilly, Special Advisor (Age 58) When did Aimmune Therapeutics IPO? (AIMT) raised $124 million in an IPO on Thursday, August 6th 2015. The company issued 8,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Credit Suisse and Piper Jaffray acted as the underwriters for the IPO. Has Aimmune Therapeutics been receiving favorable news coverage? News articles about AIMT stock have been trending somewhat positive this week, Accern Sentiment reports. Accern identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Aimmune Therapeutics earned a media and rumor sentiment score of 0.16 on Accern's scale. They also assigned news stories about the biotechnology company an impact score of 46.91 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future. View Recent Headlines for Aimmune Therapeutics. Who are Aimmune Therapeutics' major shareholders? Aimmune Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.28%), FMR LLC (4.35%), Point72 Asset Management L.P. (2.89%), Eagle Asset Management Inc. (2.32%), Victory Capital Management Inc. (1.18%) and Emerald Advisers Inc. PA (0.78%). Company insiders that own Aimmune Therapeutics stock include Bakker Juliet Tammenoms, Daniel C Md Adelman, Douglas T Sheehy, Eric Bjerkholt, Kathryn E Falberg, Mary M Rozenman, Patrick G Enright, Stephen George Dilly, Susan E Barrowcliffe and Warren L Desouza. View Institutional Ownership Trends for Aimmune Therapeutics. Which major investors are selling Aimmune Therapeutics stock? AIMT stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Millennium Management LLC, Eagle Asset Management Inc., Federated Investors Inc. PA, Alps Advisors Inc., Emerald Advisers Inc. PA and Alpine Global Management LLC. Company insiders that have sold Aimmune Therapeutics company stock in the last year include Daniel C Md Adelman, Douglas T Sheehy, Mary M Rozenman, Stephen George Dilly and Susan E Barrowcliffe. View Insider Buying and Selling for Aimmune Therapeutics. Which major investors are buying Aimmune Therapeutics stock? AIMT stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., BlackRock Inc., C WorldWide Group Holding A S, Fiera Capital Corp, Renaissance Technologies LLC, Bank of America Corp DE, Highland Capital Management LP and Los Angeles Capital Management & Equity Research Inc.. Company insiders that have bought Aimmune Therapeutics stock in the last two years include Bakker Juliet Tammenoms, Eric Bjerkholt, Kathryn E Falberg and Patrick G Enright. View Insider Buying and Selling for Aimmune Therapeutics. How do I buy shares of Aimmune Therapeutics? Shares of AIMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Aimmune Therapeutics' stock price today? One share of AIMT stock can currently be purchased for approximately $27.90. How big of a company is Aimmune Therapeutics? Aimmune Therapeutics has a market capitalization of $1.66 billion. The biotechnology company earns $-131,320,000.00 in net income (profit) each year or ($2.61) on an earnings per share basis. Aimmune Therapeutics employs 131 workers across the globe. How can I contact Aimmune Therapeutics? Aimmune Therapeutics' mailing address is 8000 MARINA BOULEVARD SUITE 300, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-614-5220 or via email at [email protected] MarketBeat Community Rating for Aimmune Therapeutics (NASDAQ AIMT)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 266 (Vote Outperform)Underperform Votes: 168 (Vote Underperform)Total Votes: 434MarketBeat's community ratings are surveys of what our community members think about Aimmune Therapeutics and other stocks. Vote "Outperform" if you believe AIMT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AIMT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 8/17/2018 by MarketBeat.com StaffFeatured Article: What is a Leveraged Buyout (LBO)?